If this is your first visit, be sure to check out the FAQ & read the forum rules. To view all forums, post or create a new thread, you must be an AAPC Member. If you are a member and have already registered for member area and forum access, you can log in by clicking here. If you've forgotten your username or password use our password reminder tool. To start viewing messages, select the forum that you want to visit from the selection below..
Good morning! Trying to find any information in regards to new Evusheld - Tixagevimab and cilgavimab codes for drug and administration. Has anybody found information on when these new codes will be released?
Thank you for the above.
Would the payable diagnosis code be Z20.822?
In the EUA for this monoclonal antibody therapy it is not to be used for post-exposure or for a confirmed case of COVID-19.
But per the guidelines, since we are in a global pandemic, everyone in the world has "suspected exposure" at all times.
From my research it shows that it would be appropriate to report Z20.822 for M0220&M0221.
Does anyone have any other guidance that contradicts this?